Published in Cancer Weekly, October 25th, 2005
The primary author of the article is Charles Butts of the Cross Cancer Institute, the lead investigator for the phase 2b study.
The survival results previously released and now published indicated a 4.4 month longer median survival for patients randomized to the BLP25 Liposome Vaccine (L BLP25) arm (88 patients) compared to the Best Supportive Care (BSC) arm (83 patients).
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.